Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in XXXX : data from the PRIMARYS study.

@entity1 @entity1987 @entity1109 @entity442 @entity2124 @entity2012
PURPOSE: To evaluate the effects of lanreotide Autogel on @entity1 -reported outcomes and association with biochemical control, using PRIMARYS data. METHODS: PRIMARYS was a 1-year, open-label study of lanreotide Autogel (Depot in USA) 120  mg every 4  weeks in 90 treatment-na  ve @entity1 with @entity2012 . Symptoms were assessed using @entity1 -assessed @entity2012 Symptom Questionnaire (PASQ) and health-related quality of life (HRQoL) using the AcroQoL questionnaire. Correlations between PASQ and AcroQoL scores, and between PASQ/AcroQoL and @entity2124 (GH)/insulin-like growth factor-1 ( @entity442 ) levels were also evaluated (post hoc). RESULTS: @entity1109 and HRQoL significantly improved from week  12 to week  48, with modest correlations at week 48 between PASQ total score (R  =  -0.55, p  <  0.0001) and AcroQoL global and physical scores (R  =  -0.67, p  <  0.0001). Approximately 60  % of @entity1 achieved a @entity1987 ( @entity1987 ; improvement >50  % of baseline standard deviation) in PASQ total score and >40  % achieved a @entity1987 in AcroQoL global score (post hoc). Changes in PASQ scores were similar in biochemically controlled ( @entity2124 levels  <=2.5   g/L and normal @entity442 levels) and uncontrolled groups, while changes in global and psychological AcroQoL scores were greater in the controlled group. There was no correlation between changes in PASQ or AcroQoL scores and changes in @entity2124 or @entity442 levels. CONCLUSIONS: Primary treatment with lanreotide Autogel over 1  year was associated with rapid and sustained improvements in clinical signs and symptoms and HRQoL in @entity1 with @entity2012 . Improvements in HRQoL, but not symptoms, were greater in those achieving biochemical control (ClinicalTrials.gov: NCT00690898; EudraCT: 2007-000155-34).
